Kymriah savings card from the maker

Kymriah is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Kymriah is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameKymriah

Authorized generictisagenlecleucel

Regular generictisagenlecleucel

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Kymriah?

The original

–

Brand nameThe maker’s card

KYMRIAH CARES co-pay assistance

Savings card from Novartis

Kymriah’s maker has a savings program. Its page doesn’t list a dollar amount.

Or call 1-844-459-6742.

From the maker’s site, checked November 2, 2026. Check the maker’s page for who can use it.

Authorized genericNot sold

There isn’t one. An authorized generic is Kymriah itself, from the same company, sold without the brand name, and usually for less. For now Kymriah is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Kymriah is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:

Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Limitations of Use: KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma.
Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Source: the FDA label for Kymriah (Novartis Pharmaceuticals Corporation), December 16, 2025. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Check the maker’s page for who can use it.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/kymriah/